Page 23 - Read Online

Page 318 Ong et al. Neuroimmunol Neuroinflammation 2020;7:311-8 I http://dx.doi.org/10.20517/2347-8659.2020.05

Ethical approval and consent to participate
Informed consent, either verbal or written, was obtained from patients for the use of retrospective data
with longitudinal follow-up for this study.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2020.

REFERENCES
1. Wingerchuk DM, Hogancamp WF, O’Brien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devic’s syndrome).
Neurology 1999;53:1107-14.
2. Marrie RA, Gryba C. The incidence and prevalence of neuromyelitis optica: a systematic review. Int J MS Care 2013;15:113-8.
3. Viswanathan S, Wah LM. A nationwide epidemiological study on the prevalence of multiple sclerosis and neuromyelitis optica spectrum
disorder with important multi-ethnic differences in Malaysia. Mult Scler 2019;25:1452-61.
4. Ganesh A. Practice current: how do you treat neuromyelitis optica? Neurol Clin Pract 2017;7:170-8.
5. Bedi GS, Brown AD, Delgado SR, Usmani N, Lam BL, et al. Impact of rituximab on relapse rate and disability in neuromyelitis optica.
Mult Scler 2011;17:1225-30.
6. Cree BA, Lamb S, Morgan K, Chen A, Waubant E, et al. An open label study of the effects of rituximab in neuromyelitis optica.
Neurology 2005;64:1270-2.
7. Cabre P, Mejdoubi M, Jeannin S, Merle H, Plumelle Y, et al. Treatment of neuromyelitis optica with rituximab: a 2-year prospective in
multicentre study. J Neurol 2018;265:917-25.
8. Jacob A, Weinshenker BG, Violich I, McLinskey N, Krupp L, et al. Treatment of neuromyelitis optica with rituximab: Retropective
analysis of 25 patients. Arch Neurol 2008;65:1443-8.
9. Greenberg BM, Graves D, Remington G, Hardeman P, Mann M, et al. Rituximab dosing and monitoring strategies in neuromyelitis optica
patients: creating strategies for therapeutic success. Mult Scler 2012;18:1022-6.
10. Kim SH, Kim W, Li XF, Jung IJ, Kim HJ. Repeated treatment with rituximab based on the assessment of peripheral circulating memory
B cells in patients with relapsing neuromyelitis optica over 2 years. Arch Neurol 2011;68:1412-20.
11. Akaishi T, Nakashima I, Takahashi T, Abe M, Ishii T, et al. Neuromyelitis optica spectrum disorders with unevenly clustered attack
occurrence. Neurol Neuroimmunol Neuroinflamm 2019;7:e640.
12. Pellkofer HL, Krumbholz M, Berthele A, Hemmer B, Gerdes LA, et al. Long term follow up of patients with neuromyelitis optica after
repeated therapy with rituximab. Neurology 2011;76:1310-5.
13. Fernandez-Megia MJ, Casanova-Estruch B, Perez-Miralles F, Ruiz-Ramos J, Alcala-Vincente C, et al. Clinical evaluation of rituximab
treatment for neuromyelitis optica. Neurologia 2015;30:461-4.
14. Lindsey JW, Meulmester KM, Brod SA, Nelson F, Wolinsky JS. Variable results after rituximab in neuromyelitis optica. J Neurol Sci
2012;317:103-5.
15. Lp VH, Lau AY, Au LW, Fan FS, Chan AY, et al. Rituximab reduces attacks in Chinese patients with neuromyelitis optica spectrum
disorders. J Neurol Sci 2013;324:38-9.
16. Jade JD, Bansi S, Singhal B. Rituximab in neuromyelitis optica spectrum disorders: our experience. Ann Indian Acad Neurol
2017;20:229-32.
17. Kim SH, Kim Y, Kim G, Park NY, Jang HM, et al. Less Frequent Rituximab Retreatment Maintains Remission of Neuromyelitis Optica
Spectrum Disorder, Following Long-Term Rituximab Treatment. J Neurol Neurosurg Psychiatry 2019;90(4):486-7.
18. Lin J, Li X, Xue B, Tong Q, Chen Z, et al. Low-dosage of rituximab in Chinese patients with neuromyelitis optica spectrum disorder. J
Neuroimmunol 2018;317:1-4.
19. Yang CS, Yang L, Li T, Zhang DQ, Jin WN, et al. Responsiveness to reduced dosage of rituximab in Chinese patients with neuromyelitis
optica. Neurology 2013;81:710-3.
20. Danés I, Agustí A, Vallano A, Martínez J, Alerany C, et al. Available Evidence and Outcome of Off-Label Use of Rituximab in Clinical
Practice. Eur J Clin Pharmacol 2013;69:1689-99.
21. Damato V, Evoli A, Iorio R. Efficacy and safety of rituximab therapy in neuromyelitis optica spectrum disorders: a systematic review and
meta-analysis. JAMA Neurol 2016;73:1342-8.
22. Novi G, Bovis F, Capobianco M, Frau J, Mataluni G, et al. Efficacy of different rituximab therapeutic strategies in patients with
neuromyelitis optica spectrum disorders. Mult Scler Relat Disord 2019;36:101430.